BridgeBio Pharma (BBIO) Convertible Debt (2020 - 2025)

BridgeBio Pharma has disclosed Convertible Debt across 6 years of filings, most recently posting $546.1 million for Q2 2025.

• Convertible Debt for Q2 2025 came in at $546.1 million, down 25.99% year-over-year; the trailing twelve-month figure through Jun 2025 was $546.1 million (down 25.99% YoY), and the FY2024 annual result was $738.9 million, up 35.98% from the prior year.
• Convertible Debt came in at $546.1 million for Q2 2025 at BridgeBio Pharma, roughly flat from $545.6 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $738.9 million in Q4 2024 to a low of $539.9 million in Q4 2021.
• The 5-year median for Convertible Debt is $638.9 million (2021), against an average of $639.0 million.
• Across the five-year window, Convertible Debt jumped 98.35% in 2021 and dropped 26.16% in 2022, its largest moves.
• BridgeBio Pharma's Convertible Debt stood at $539.9 million in 2021, then soared by 36.13% to $735.0 million in 2022, then slipped by 26.07% to $543.4 million in 2023, then jumped by 35.98% to $738.9 million in 2024, then dropped by 26.09% to $546.1 million in 2025.
• The last three Convertible Debt figures came in at $546.1 million (Q2 2025), $545.6 million (Q1 2025), and $738.9 million (Q4 2024), per Business Quant data.